
Overview
Dystrogen Therapeutics is a clinical-stage biotechnology company developing chimeric cell therapy for muscle wasting disorders, especially Duchenne muscular dystrophy (DMD). It is testing DEC cell therapy, designed to work across DMD genetic mutations without immunosuppression. The company reports outcomes such as increased muscle force, reduced fatigue, and larger muscle fiber diameter and volume.
Financials
Industry
Offer
- Chimeric cell therapy
- Duchenne muscular dystrophy therapy
- Clinical trials
Websites
- dystrogen.comHome - Dystrogen Therapeutics CorporationWordPress 5.8ElementorGoogle AnalyticsGoogle Tag ManagerYoast SEOApache
Authorized Representatives
Manner of representation
Each member of the management board acting independently is authorized to make declarations of will on behalf of the company and to represent the company.
Supervisory board
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Was a VAT taxpayer from 2018-03-30 to 2024-06-14.
Reason for removal: Art. 96 ust. 9 pkt 2 (contact with the taxpayer or their representative is impossible despite documented attempts)
Debt
No entries in the National Debtors Register (KRZ).
MSiG notices
| Publication date | Event | |
|---|---|---|
| Feb 18, 2025 | Dissolution without liquidation opened | |
| Nov 18, 2022 | Dissolution without liquidation opened | |
| Sep 3, 2019 | Commercial Companies Code notice |
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Aug 2, 2019 | De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier) | $4,622$4,622 | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości | |
| Nov 17, 2017 | Aid for SME access to finance — aid for start-ups | $381.2K$381,184 | Dyrektor Narodowego Centrum Badań i Rozwoju |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Famicordtx S.A. | $589,673.84 | famicordtx.com | ||
| Pharmena S.A. | $541,436.46 | pharmena.eu | ||
| VET Cell Tech sp. z o.o. | $483,439.81 | vetcelltech.com | ||
| Vaxican sp. z o.o. | $390,933.79 | vaxican.com | ||
| Personather sp. z o.o. | $47,478.47 | personather.pl | ||
| Biolabic sp. z o.o. | $37,688.85 | biolabic.pl | ||
| DR Joanna Sanford sp. k. | $28,674.82 | sanfordbiotech.com | ||
| Cellis sp. z o.o. | $24,935.59 | cellis.eu | ||
| Bioinfobank Capital sp. z o.o. | $6,252.45 | bioinfo.pl | ||
| Synerga.Fund S.A. | $3,772.65 | synergafund.com.pl |
Change history
| Date | Event | |
|---|---|---|
| 2019-10-22 | Share capital increase (171,886.68 PLN → 179,220.00 PLN) | |
| 2018-02-19 | Entered in the register |
FAQ
Last updated: 2026-03-29